New hope for younger leukemia patients: experimental drug combo trial shows promise
NCT ID NCT02158091
Summary
This study is testing whether adding a new drug called IPI-145 to standard chemotherapy works better for younger patients with untreated chronic lymphocytic leukemia (CLL). Researchers want to find the safest dose and see if this combination can eliminate more cancer cells than standard treatment alone. The trial involves 32 participants aged 18-65 who haven't had any previous CLL treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beth Isreal Deaconess Medical Center
Boston, Massachusetts, 02115, United States
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02115, United States
Conditions
Explore the condition pages connected to this study.